



PCT/ 615200 2/00 4110



INVESTOR IN PEOPLE

#2

10/528742

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road

Newport

South Wales 06 NOV 2003

NP10 8QQ

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Andrew Gurney

Dated 14 October 2003

BEST AVAILABLE COPY

at Form 1/77

Patents Act 1977
rule 16)

27 SEP 1977

Request for grant of a patent

See the notes on the back of this form. You can also
obtain an explanatory leaflet from the Patent Office to
help you fill in this form)

The Patent Office

1/77

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Your reference

P0319409B

28SEP02 E751706-8 000019
P01/7700 0 00-0222527.4

Patent application number
(The Patent Office will fill in this part)

0222527.4

Full name, address and postcode of the or of
each applicant (underline all surnames)

JOHNSON & JOHNSON MEDICAL LIMITED
Erskine House
68-73 Queen Street
Edinburgh
United Kingdom
EH2 4NH

Patents ADP number (if you know it)

6008031002

If the applicant is a corporate body, give the
country/state of its incorporation

UK (Scotland)

Title of the invention

WOUND TREATMENT DEVICE

Name of your agent (if you have one)

Carpmaels & Ransford

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

43 Bloomsbury Square
London
WC1A 2RA

Patents ADP number (if you know it)

83001

If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)

Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an
applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 10

Claim(s) 2

Abstract 1

Drawing(s) 1

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Carpmaels - Ransford
Carpmaels & Ransford

Date

27th September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. Anthony James

020-7242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

WOUND TREATMENT DEVICE

The present invention relates to articles that can provide controlled delivery of one or more therapeutic agents to a wound.

5

The amount and composition of wound fluid (exudate) produced by a wound depends on the type of wound and the history of wound healing. For example, surgical wounds have an acute inflammatory phase of a few days during which discharge is significant, after which the rate of exudate production can be expected to fall sharply. Chronic wounds, such as ulcers, produce wound fluid containing elevated levels of protease enzymes. Infected wounds generally produce substantially more exudate than non-infected wounds, and the composition of the wound fluid is different. Burns produce large amounts of wound exudate having characteristic properties.

15

Infection of wounds by bacteria delays the healing process, since bacteria compete for nutrients and oxygen with macrophages and fibroblasts, whose activities are essential for the healing of the wound. Infection results when bacteria achieve dominance over the systemic and local factors of host resistance. Infection is therefore a manifestation of a disturbed host/bacteria equilibrium in favour of the invading bacteria. This elicits a systemic septic response, and also inhibits the multiple processes involved in wound healing. Lastly, infection can result in a prolonged inflammatory phase and thus slow healing, or may cause further necrosis of the wound. The granulation phase of the healing process will begin only after the infection has subsided.

Chronically contaminated wounds all contain tissue bacterial flora. These bacteria may be indigenous to the patient or might be exogenous to the wound. Closure, or eventual healing of the wound is often based on a physician's ability to control the level of the bacterial flora.

If clinicians could respond to wound infection as early as possible the infection could be treated topically as opposed to having to use antibiotics. This would also

There is thus a need for a wound treatment device that will selectively release therapeutic agents such as antimicrobial agents and/or pain relieving agents into wounds only when there is a clinical need. Such a device could provide early intervention with suitable treatment (e.g. a topical antimicrobial treatment) before
5 severe clinical symptoms or wound chronicity sets in.

In a first aspect, the present invention provides a wound treatment device comprising a water-impermeable envelope having at least one aperture, wherein the envelope contains a therapeutic substance, and wherein the at least one
10 aperture in the envelope is blocked by a material that breaks down in the presence of one or more components of wound fluid thereby permitting the active substance to contact the wound fluid.

The term "envelope" refers to a small package or enclosure that can be inserted
15 onto or into a wound. It is preferably covered by a secondary dressing to hold it in place and provide absorbency for wound fluid. The package is substantially impermeable to liquid water until the aperture is opened by the action of one or more components present in wound fluid. The wound fluid and/or the wound is not exposed to the therapeutic agent inside the envelope until the aperture is opened,
20 and this enables the treatment to be tailored to predetermined wound conditions and unnecessary medication to be avoided. The device can be used in conjunction with a wide range of existing wound dressings, and is sufficiently small that it will not interfere with the absorbency of such dressings.

25 In certain embodiments the envelope is formed substantially from flexible sheet material. Preferably, it consists essentially of such material, such as thermoplastic film, for example in the form of a sachet. Suitable thermoplastics include polyolefins such as polyethylene, copolymers such as ethylene methyl acrylate, or fluoropolymers such as polyvinylidene fluoride. Such envelopes are extremely low
30 cost and can be made in a broad range of sizes and shapes enabling them to be applied to all types of wounds, including cavity wounds.

Preferably, the aperture or apertures take up only a small part of the area of the envelope, since the barrier materials are generally more expensive than the sheet materials used to form the envelope. In certain embodiments, the total area of the apertures in the envelope is from about 0.01 to about 1cm². Preferably, the envelope has fewer than 10 such apertures, more preferably fewer than 5, and most preferably only one such aperture. Typically, the apertures make up from about 0.1% to about 50% of the surface area of the envelope, more typically from about 1% to about 30%, and preferably from about 1% to about 10% of the surface area of the envelope.

10

The mean area of each aperture may for example be from about 1 to about 400 mm², preferably from about 2 to about 200 mm², and more preferably about 10 to about 100 mm².

15 The apertures in the envelope are blocked by a material that breaks down in wound fluid to open the apertures. The breakdown of the barrier material may be by dissolution, or by enzymatic or other chemical degradation by the ingredients of wound fluid. In certain embodiments, the barrier material breaks down preferentially in heavily exuding wounds. In certain embodiments, the degradable material breaks down preferentially in infected wounds.

20

For example, the barrier material may comprise a water soluble material, such as a water soluble macromolecule. At medium to high levels of exudate the soluble material is dissolved by the exudate, thus opening the apertures. At low levels of exudate or where there is a dry wound the soluble material will stay in place so that the apertures in the device remain occluded.

25

Suitable soluble materials for partially or completely occluding the apertures include water soluble macromolecular materials (hydrogels) such as sodium alginate, sodium hyaluronate, alginate derivatives such as the propylene glycol alginate described in EP-A-0613692, and soluble hydropolymers formed from vinyl alcohols, vinyl esters, vinyl ethers and carboxy vinyl monomers, meth(acrylic) acid, acrylamide, N-vinyl pyrrolidone, acylamidopropane sulphonic acid, PLURONIC

30

(Registered Trade Mark) (block polyethylene glycol, block polypropylene glycol) polystyrene-, maleic acid, NN-dimethylacrylamide diacetone acrylamide, acryloyl morpholine, and mixtures thereof. Suitable hydrogels are also described in US-A-5352508.

5

Other suitable materials for occluding the apertures of the device are polymeric materials that are not soluble in water, but that are bioerodible in wound fluid. Examples include polylactide/polyglycolide copolymers, oxidized regenerated cellulose, chitosan, chitin, and mixtures thereof.

10

Other suitable materials for partially or completely occluding the apertures of the envelope are pH-sensitive materials that are substantially insoluble in water at 25°C under acidic conditions, but substantially soluble in water at 25°C under neutral or alkaline conditions. Whilst it is no simple matter to determine the actual
15 pH at a wound site, it appears that the pH of chronic or infected wounds is neutral or slightly alkaline, whereas the pH of intact skin is slightly acidic (pH 4 or 5).

Preferably, the pH-sensitive material is substantially insoluble in water at 25°C and pH 4 and substantially soluble in water at 25°C and pH 8. Preferably, the polymer
20 becomes soluble with increasing pH at a pH in the range of 5 to 7, more preferably 5.5 to 6.5. In this context the term "soluble" preferably denotes an equilibrium solubility of the material greater than 1%w/w in water at 25°C. Particularly suitable are film-forming polymers and mixtures, such as those used to provide enteric coatings on orally administered medicaments.

25

Preferably, the pH-sensitive material comprises a polymer selected from the group consisting of cellulose derivatives, starch derivatives, pectins, polyacrylates, polyvinyl acetate phthalate, and mixtures thereof.

30 Preferred cellulose derivatives are selected from cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, oxidised regenerated cellulose, and mixtures thereof.

Preferred polyacrylates are selected from the copolymers of methacrylic acid with methyl methacrylate. Particularly preferred are various copolymers of this type sold under the Registered Trade Mark EUDRAGIT. By varying the ratio of
5 methacrylic acid to methyl methacrylate it is possible to control the pH at which these copolymers dissolve in order to optimise the properties of the material.

In yet other embodiments, the degradable material occluding the aperture comprises a substrate for an enzyme present in wound fluid.

10

For example, it has been discovered that wound fluid from infected wounds, and from wounds that are apparently not clinically infected but which go on to become infected within a few days, have high levels of neutrophil elastase activity and may also have high levels of other inflammatory enzymes, such as macrophage
15 proteases, other neutrophil proteases, bacterial collagenase, plasmin, hyaluronidase, kallikrein or t-PA. It is also known that the wound fluid produced by chronic wounds such as diabetic ulcers, decubitus ulcers or venous ulcers, have elevated levels of protease enzymes. Hence, the use of enzyme substrates enables the properties of the devices according to the present invention to be
20 responsive selectively to wound infection and wound chronicity.

Preferred enzyme substrates for use in the degradable material comprise a substance selected from the group consisting of elastin, fibronectin, collagen, crosslinked gelatin, fibrinogen, casein, hyaluronic acid, plasminogen, fibrin, chitin,
25 chitosan, oxidized cellulose, polylactide/polyglycolide copolymers, and mixtures thereof.

In preferred embodiments, the materials for partially or completely occluding the apertures of the envelope comprise substrate materials for one or more protease
30 enzymes present in wound fluid, especially infected wound fluid. Such proteases include elastase, collagenase, pectinase, matrix metalloproteinases, and mixtures thereof. Preferred substrate materials include substances selected from the group

consisting of elastin, fibronectin, collagen, crosslinked gelatin, fibrinogen, casein, hyaluronic acid, plasminogen, fibrin, and mixtures thereof.

5 The barrier composition may comprise at least 25%, more preferably at least 50% w/w based on the weight of the composition of the soluble macromolecular materials, pH-sensitive materials, or substrate materials on a dry weight basis. The barrier composition may further comprise from about 5 to about 50% by weight, preferably from 15 to 40% by weight, on the same basis of one or more humectants and/or plasticisers such as glycerol, sorbitol or polyethylene glycol.

10

The one or more therapeutic agents may be any substance suitable for the treatment of wounds. In certain embodiments the therapeutic agents are selected from the group consisting of antiseptics, antibiotics, analgesics, steroids and growth factors. Preferred therapeutic agents are antimicrobial agents including
15 metallic silver, silver salts and compounds such as silver sulfadiazine, povidone iodine, chlorhexidine and mixtures thereof, and analgesic agents including benzocaine, lidocaine and mixtures thereof.

The therapeutic agent may be present in the envelope in particulate or soluble or
20 otherwise dispersible form, so that it can pass out of the envelope into the wound once the aperture is opened by the action of wound fluid. In other embodiments, the therapeutic agent may be retained inside the envelope even after the aperture has opened, for example by being dispersed in or on a substrate that is too large to fit through the aperture. An example would be a silver treated cloth.

25

In certain embodiments the therapeutic material inside the envelope is adapted to provide sustained release of the therapeutic agent in wound fluid. For example, the material may comprise a bioerodible substance having the therapeutic agents dispersed or encapsulated therein. Suitable bioerodible substances include
30 proteins such as albumin, collagen, cross-linked gelatin or zein, polysaccharides such as oxidized regenerated cellulose, biodegradable synthetic polymers such as polylactate/polyglycolate copolymers, glycosaminoglycans such as hyaluronate, and mixtures thereof.

In certain embodiments, the therapeutic material may be dispersed in or on particles suitable for drug delivery. The particles may be made by any suitable technique, including comminution, coacervation, or two-phase systems for example as described in US-A-3886084. Techniques for the preparation of medicated microspheres for drug delivery are reviewed, for example, in Polymeric Nanoparticles and Microspheres, Guiot and Couvreur eds., CRC Press (1986). The microparticles are preferably loaded with from 1 to 90 wt.%, more preferably from 3 to 50 wt.% of the therapeutic agents.

10

Preferably, the wound treatment device according to the present invention is sterile and packaged in a microorganism-impermeable container.

In a second aspect, the present invention provides a wound dressing comprising a wound treatment device according to the present invention.

In a third aspect, the present invention provides a method of treatment of a wound comprising applying thereto a device according to the present invention. Preferably, the method further comprises applying a wound dressing over the device.

20

An embodiment of the present invention will now be described further, by way of example, with reference to the accompanying drawings, in which:

Figure 1 shows a perspective view partially cut away of a wound treatment device according to the invention; and

25

Figure 2 shows a longitudinal cross-sectional view of the dressing of Fig. 1.

Example 1

Referring to Figure 1, the wound treatment article 1 comprises an envelope 2 of substantially liquid-impermeable sheet material. The envelope consists of front and back faces 3,4 of a continuous polypropylene film that are heat bonded around their and edge margin 5 to form a waterproof sachet. Inside the envelope

30

there is a rectangular sheet 6 of silver-impregnated antimicrobial cloth. The envelope comprises an aperture 7 occluded by a collagenase-degradable film composition 8

- 5 The device is prepared as follows. 1g of collagen fibers formed by freeze drying Type I collagen extracted from limed bovine hide were suspended in 100ml of 0.05M acetic acid. This suspension was poured into a plastic dish to a thickness of 4mm. The dish was placed in a drying cabinet at room temperature until the weight of the suspension had reduced to 50% of the initial weight. At this stage
- 10 the apertured polymer sheet that will form the apertured face 3 of the envelope was placed on the surface of the collagen suspension. The suspension was then fully dried and peeled from the square dish. The resulting material has the aperture of the sheet occluded by a thin film of Type I collagen. The apertured sheet 3 with the layer of collagen 8 applied thereto was then assembled into the
- 15 device by heat bonding to the back sheet 4, with the antimicrobial cloth inserted between the sheets 3 and 4.

The device is packaged in a microorganism-impermeable pouch (not shown), and sterilised using gamma radiation.

20

- In use, the device 1 is removed from the package, and the article is applied to the wound and held in place by a sterile and absorbent secondary dressing. The dissolution of the collagen contained in the barrier layer 8 in the presence of elevated levels of collagenase exposes the wound fluid to the antimicrobial silver
- 25 cloth inside the envelope in response to increased collagenase production by infected or chronic wounds.

Example 2

- 30 In another embodiment, the barrier layer 8 contained chitosan as the biodegradable component. The chitosan containing film composition prepared as follows.

100.0 grams of chitosan chloride was mixed in 1.5 liters of water until blended. 200.0 grams of glycerol were blended into the mixture, after which 200.0 grams of polyethylene glycol ("PEG") were then added. The resulting mixture was then filtered and coated over the aperture as described in Example 1. The mixture was
5 then frozen and freeze dried, or air dried in circulating air at room temperature.

The above embodiments have been described by way of example only. Many other embodiments falling within the scope of the accompanying claims will be apparent to the skilled reader.

CLAIMS

1. A wound treatment device comprising a water-impermeable envelope having at least one aperture, wherein the envelope contains a therapeutic substance, and wherein the at least one aperture in the envelope is blocked by a degradable material that breaks down in the presence of one or more components of wound fluid thereby permitting the therapeutic substance to contact the wound fluid.
2. A wound treatment device according to claim 1, wherein the envelope is formed substantially from flexible sheet material.
3. A wound treatment device according to claim 1 or 2, wherein the total area of the apertures in the envelope is from about 0.01 to about 1cm².
4. A wound treatment device according to claim 1, 2 or 3, wherein the envelope has only one said aperture.
5. A wound treatment device according to any preceding claim, wherein the degradable material breaks down preferentially in infected wounds.
6. A wound dressing according to any preceding claim, wherein the degradable material comprises a substrate for an enzyme present in wound fluid.
7. A wound treatment device according to any preceding claim, wherein the degradable material comprises a substance selected from the group consisting of elastin, fibronectin, collagen, crosslinked gelatin, fibrinogen, casein, hyaluronates, plasminogen, fibrin, chitin, chitosan, oxidized cellulose, polylactide/polyglycolide copolymers, and mixtures thereof.
8. A wound treatment device according to any preceding claim wherein the therapeutic agents are selected from the group consisting of antiseptics, antibiotics, analgesics, steroids and growth factors, and mixtures thereof.

9. A wound treatment device according to claim 8, wherein the therapeutic agents comprise an antimicrobial agent selected from colloidal silver, silver sulfadiazine, povidone iodine, chlorhexidine, and mixtures thereof.

5

10. A wound treatment device according to any preceding claim, wherein the device is adapted to provide sustained release of the therapeutic agent into the wound fluid following the opening of the aperture.

10 11. A wound treatment device according to any preceding claim, wherein the therapeutic substance is dispersed in or on a solid substrate

12. A wound treatment device according to any preceding claim, wherein the therapeutic agent is dispersed or encapsulated in a bioerodible substance.

15

13. A wound treatment device according to claim 12, wherein the bioerodible substance is selected from the group consisting of proteins, polysaccharides, biodegradable synthetic polymers, glycosaminoglycans, and mixtures thereof.

20 14. A wound treatment device according to any preceding claim which is sterile and packaged in a microorganism-impermeable container.

15. A wound dressing comprising a wound treatment device according to any preceding claim.

25

ABSTRACT

WOUND TREATMENT DEVICE

- 5 A wound treatment device comprising a water-impermeable envelope having at least one aperture, wherein the envelope contains a therapeutic substance, and wherein the at least one aperture in the envelope is blocked by a material that breaks down in the presence of one or more active components of wound fluid thereby permitting the therapeutic substance to contact the wound fluid.
- 10 Preferably, the aperture is blocked by a material that is a substrate for an enzyme present in wound fluid, such as a protease.

1/1

Fig. 1





Fig. 2



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.